Clinical trial
Arsenic Trioxide in Treating Men With Germ Cell Cancer
NCT00036842 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00036842 |
|---|---|
| Title | Arsenic Trioxide in Treating Men With Germ Cell Cancer |
| Official title | Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Apr 1, 2002 |
| Completion | Jun 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: